サンプル依頼リスト カート
  • English
  • Korean
表紙：API（原薬）の世界市場-2023年～2030年
市場調査レポート
商品コード
1319149

API（原薬）の世界市場-2023年～2030年

Global Active Pharmaceutical Ingredients Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.70円
API（原薬）の世界市場-2023年～2030年
出版日: 2023年07月31日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

世界のAPI（原薬）市場は2022年に1,972億米ドルに達し、2030年には3,137億米ドルに達するなど、有利な成長が見込まれています。世界のAPI（原薬）市場は、予測期間中（2023-2030年）に6.1%のCAGRを示すと予測されています。

API（API（原薬））は医薬品の重要な構成要素です。APIは生理学的に活性な化学物質であり、医薬品の望ましい治療効果をもたらします。APIは天然由来または化学的に合成され、安全性と有効性を保証するために広範な試験と品質管理が行われます。

原薬は医薬品に不可欠な成分であり、安全で効果的な医薬品を供給する上で重要な役割を果たしています。原薬は、治療効果、製造手順、研究開発、規制遵守、信頼できる世界医薬品サプライチェーンの維持に不可欠です。

市場ダイナミクス

製造手順の増加が市場成長を牽引

医薬品製造工場の増加は、市場の成長を促進します。例えば、2023年5月3日、ベーリンガーインゲルハイムはドイツ本社で、臨床試験用のAPI（原薬）と医薬品を製造する2億8,500万ユーロ（3億1,500万米ドル）の新工場の建設を開始しました。ケミカル・イノベーション・プラントは、ドイツのインゲルハイムにあるベーリンガー・インゲルハイム本社に2026年に開設される予定です。

さらに2023年6月13日、ノボノルディスク社は、デンマークのヒレロドにある製造施設の拡張に、2023年から159億デンマーククローネ（22億9,000万米ドル）を投資する意向を発表しました。この新たな投資により、同社は将来の需要を満たす能力を拡大し、将来の臨床後期製品ポートフォリオの開発を可能にします。この資金は、将来の重篤な慢性疾患治療薬ポートフォリオを発展させるため、デンマークの既存原薬製造工場の開発に使用されます。その結果、前述の要因が市場拡大に寄与することになります。

技術進歩による原薬製造が市場成長を後押し

連続処理と工程のコンピュータ化は、大規模でコスト効率に優れた効率的な生産を可能にする2つの新しいAPI製造技術です。自動機械、コンピュータ制御工程記述（CPD）システム、デジタル製造システムは現在、原薬の処方精度を向上させ、全体的な効率を高め、手作業の必要性を排除するために使用されています。

例えば、2023年2月15日、ピラマル・ファーマ・リミテッドの子会社で、患者を対象とした開発・製造受託機関（CDMO）であるピラマル・ファーマ・ソリューションズは、米国ミシガン州リバービューの施設において、新しいリアクター・スイートでAPI（原薬）（API）の初期バッチの生産を開始したと発表しました。このように、技術開拓は市場拡大に貢献しています。

高い製造コストが市場成長の妨げに

様々な原材料のコストは、その入手可能性と需要に影響される可能性があります。特定の原材料の供給に限りがある場合や、新薬開発や市場力学の変化などの理由で需要が増加した場合、原材料価格は上昇する可能性があります。為替レートの変動や地政学的な考慮も原料価格に影響を与える可能性があります。

原薬の原材料費は、医薬品製造費全体の構成要素の一つに過ぎないことに注意することが重要です。医薬品の最終コストに影響を与えるその他の要因には、製造手順、品質管理、規制遵守、生産規模などがあります。これらの要因は、予測期間を通じて市場の拡大を妨げています。

COVID-19影響分析

世界のAPI市場はCOVID-19の流行によって恩恵を受けた。医薬品部門は、高熱、咳、風邪などのCOVID-19関連症状の治療の最前線にいた。パンデミックの間、製薬部門の人気上昇により原薬市場が成長しました。世界保健機関（WHO）がCOVID-19の大流行をパンデミック（世界的大流行）と宣言した後、有名な製薬会社やバイオ医薬品会社、若い新興企業など、さまざまな企業がワクチン開発に乗り出しました。

ロシア・ウクライナ紛争の影響分析

ロシア・ウクライナ紛争は、この地域の主要な市場プレーヤーの数が少ないことから、世界の原薬市場に与える影響は中程度と推定されます。しかし、原材料の輸出入の影響は、予測期間中、世界の医薬品原薬市場の成長にはほとんど影響を与えないと予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 世界の老人人口の増加
      • 新薬の上市と承認
    • 抑制要因
      • 各国の薬価統制政策
    • 機会
      • 原薬需要の増加
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 ロシア・ウクライナ戦争影響分析

第8章 人工知能インパクト分析

第9章 タイプ別

  • 合成API
  • バイオテクAPI

第10章 用途別

  • 循環器
  • 糖尿病
  • 腫瘍学
  • 整形外科
  • 神経学
  • 非ステロイド性抗炎症薬
  • その他

第11章 性質別

  • ジェネリックAPI
  • イノベーターAPI

第12章 製造タイプ別

  • 子会社
  • 商社

第13章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第14章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第15章 企業プロファイル

  • Aurobindo Pharma
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc.
  • Novartis AG
  • BASF SE
  • Boehringer Ingelheim GmbH
  • Dr. Reddy's Laboratories Ltd
  • Lupin Ltd
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.

第16章 付録

目次
Product Code: PH254

Market Overview

The global active pharmaceutical ingredients market reached US$ 197.2 billion in 2022 and is expected to witness lucrative growth by reaching up to US$ 313.7 billion by 2030. The global active pharmaceutical ingredients market is expected to exhibit a CAGR of 6.1% during the forecast period (2023-2030).

APIs (Active Pharmaceutical Ingredients) are critical components of pharmaceutical products. They are the physiologically active chemicals that are responsible for a drug's desired therapeutic effect. APIs are taken from natural sources or chemically synthesised, and they are subjected to extensive testing and quality control to assure their safety and efficacy.

APIs are essential components in pharmaceutical products, and they play an important role in supplying safe and effective drugs. They are critical for treatment efficacy, manufacturing procedures, research and development, regulatory compliance, and sustaining a dependable global pharmaceutical supply chain.

MarketDynamics

Rising the Manufacturing Procedures will Drive the Market Growth

Increasing the pharma manufacturings plants helps to drive the market growth. For instance, on May 03, 2023, at its German headquarters, Boehringer Ingelheim has begun building on a new 285 million euro ($315 million) plant that will create active pharmaceutical components and medications for clinical trials. The Chemical Innovation Plant is set to open in 2026 at Boehringer's headquarters in Ingelheim, Germany.

Additionally, on June 13, 2023, Novo Nordisk has announced intentions to invest DKr15.9 billion ($2.29 billion) in expanding its manufacturing facility in Hillerod, Denmark, beginning in 2023. The new investment will expand the company's ability to satisfy future demand and allow for the development of its future clinical late-phase product portfolio. The funds will be used to develop its existing Danish API production plant in order to advance its future serious and chronic illness portfolio. As a result, the aforementioned factors contribute to market expansion.

Technological Advancements API Manufacturing Helps to Boost The Market Growth

Continuous processing and computerization of processes are two new API manufacturing technologies that enable large-scale, cost-effective, and efficient production. Automated machinery, computer-controlled process description (CPD) systems, and digital manufacturing systems are currently being used to improve API formulation accuracy, increase overall efficiency, and eliminate the need for manual labour.

For instance, on Feburary 15, 2023, Piramal Pharma Solutions, a patient-focused Contract Development and Manufacturing Organisation (CDMO) and subsidiary of Piramal Pharma Ltd, announced that it had begun of production of initial batches of active pharmaceutical ingredients (APIs) in new reactor suites at its Riverview, Michigan, USA facility. Thus, technical developments contribute to market expansion.

High Manufacturing Costs Will Hamper the Market Growth

The cost of various raw materials can be affected by their availability and demand. Raw material prices can rise if there is a limited supply of a specific raw material or if demand increases owing to reasons such as new drug development or changes in market dynamics. Currency exchange rate fluctuations and geopolitical considerations can also have an impact on raw material prices.

It is crucial to note that the raw material costs of APIs are only one component of the overall pharmaceutical manufacturing expenses. Other factors that influence the final cost of pharmaceutical products include manufacturing procedures, quality control, regulatory compliance, and production scale. These factors are impeding market expansion throughout the predicted period.

COVID-19 Impact Analysis

The global APIs market benefited by the COVID-19 epidemic. The pharmaceutical sector was in the forefront of treating COVID-19-related symptoms such as high fever, cough, and cold. The active pharmaceutical components market grew during the pandemic due to the rising popularity of the pharmaceutical sector. Following the World Health Organization's declaration of the COVID-19 outbreak as a pandemic, a varied group of known pharmaceutical and biopharmaceutical companies, as well as young startups, moved up to develop vaccines.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global active pharmaceutical ingredients market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global active pharmaceutical ingredients market growth over the forecast period.

Segment Analysis

The global active pharmaceutical ingredients market is segmented based on type, application, nature, manufacturing type and region.

Oncology Type Segment Accounts for 21.3% of Market Share

Owing to the high prevalence of cancer in the last few decades, and the disease is expected to affect a higher portion of the population during the forecast period. Key companies are constantly developing new APIs to meet worldwide demand in the oncology segment. For instance, on June 28, 2023, Merck KGaA's North American subsidiary, MilliporeSigma, has opened the doors to its $65 million high-potency active pharmaceutical ingredient (HPAPI) manufacturing plant, which will focus on cancer therapies.

HPAPIs have been discovered to be highly effective at low doses for cell killing, with few side effects for patients. They are currently being employed in innovative cancer therapeutics such as antibody-drug conjugates. As a result, the aforementioned elements contribute to segment growth.

Geographical Analysis

North America Accounted for Approximately 38.4% of the Market Share

The growing prevalence of chronic diseases, as well as increased government incentives to create innovative drugs, characterise the North American market. In addition, the increased adoption of biological pharmaceuticals among patients for the treatment of a variety of chronic illnesses is fuelling demand for the biological API segment in North America.

According to the Alzheimer's Association, roughly 7.5 million persons over the age of 60 in the United States suffer from Alzheimer's dementia, with that number expected to rise to 13 million by 2050. As a result, the rise in such chronic illnesses has fueled the expansion of this market in the North American area.

Competitive Landscape

The major global players in the active pharmaceutical ingredients market include: Aurobindo Pharma, Teva Pharmaceutical Industries Ltd, Pfizer Inc., Novartis AG, BASF SE, Boehringer Ingelheim GmbH, Dr. Reddy's Laboratories Ltd, Lupin Ltd, Mylan NV, Sun Pharmaceutical Industries Ltd among others.

Why Purchase the Report?

  • To visualize the global active pharmaceutical ingredients market segmentation based on type, application, nature, manufacturing type and region,as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of active pharmaceutical ingredients market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global active pharmaceutical ingredients market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by Nature
  • 3.4. Snippet by Manufacturing type
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the geriatric population around the world
      • 4.1.1.2. The launches of new drugs and approvals
    • 4.1.2. Restraints
      • 4.1.2.1. Drug price control policies across various countries
    • 4.1.3. Opportunity
      • 4.1.3.1. Rising demand for active pharmaceuticals ingredients
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Russia Ukraine War Impact Analysis

8. Artificial Intelligence Impact Analysis

9. By Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 9.1.2. Market Attractiveness Index, By Type
  • 9.2. Synthetic API *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Biotech API

10. By Application

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.1.2. Market Attractiveness Index, By Application
  • 10.2. Cardiovascular*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Diabetes
  • 10.4. Oncology
  • 10.5. Orthopaedics
  • 10.6. Neurology
  • 10.7. NSAIDS
  • 10.8. Others

11. By Nature

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Nature
    • 11.1.2. Market Attractiveness Index, By Nature
  • 11.2. Generic API *
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Innovator API

12. By Manufacturing type

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing type
    • 12.1.2. Market Attractiveness Index, By Manufacturing type
  • 12.2. Captive*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Merchant

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Nature
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing type
    • 13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.7.1. U.S.
      • 13.2.7.2. Canada
      • 13.2.7.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Nature
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing type
    • 13.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.7.1. Germany
      • 13.3.7.2. U.K.
      • 13.3.7.3. France
      • 13.3.7.4. Spain
      • 13.3.7.5. Italy
      • 13.3.7.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Nature
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing type
    • 13.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.7.1. Brazil
      • 13.4.7.2. Argentina
      • 13.4.7.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Nature
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing type
    • 13.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.7.1. China
      • 13.5.7.2. India
      • 13.5.7.3. Japan
      • 13.5.7.4. Australia
      • 13.5.7.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Nature
    • 13.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing type

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Market Positioning/Share Analysis
  • 14.3. Mergers and Acquisitions Analysis

15. Company Profiles

  • 15.1. Aurobindo Pharma*
    • 15.1.1. Company Overview
    • 15.1.2. Product Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. Teva Pharmaceutical Industries Ltd
  • 15.3. Pfizer Inc.
  • 15.4. Novartis AG
  • 15.5. BASF SE
  • 15.6. Boehringer Ingelheim GmbH
  • 15.7. Dr. Reddy's Laboratories Ltd
  • 15.8. Lupin Ltd
  • 15.9. Mylan NV
  • 15.10. Sun Pharmaceutical Industries Ltd.

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us